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MODAFINIL IS A WAKE-promoting medicationused in the treatment ofnarcolepsy and other
sleep disorders. Modafinil may en-
hance cognition and is used off-label
for the treatment of cognitive dysfunc-
tion in some psychiatric disorders
(ie, schizophrenia, attention-deficit/
hyperactivity disorder [ADHD]).1
Moreover, modafinil is increasingly
being diverted for nonmedical use
by healthy individuals with the expec-
tation that it will improve cognitive
performance.2 Although modafinil
apparently has very low abuse liability
(low reinforcing effects) in non–drug
abusing individuals, the Physicians’
Desk Reference cautions that it can
produce psychoactive and euphoric
effects typical of central nervous sys-
tem stimulant drugs,3 and there is
debate surrounding its potential for
abuse.4,5
The mechanisms of action of modafi-
nil are not well understood but are be-
lieved to differ from those of stimulant
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Context Modafinil, a wake-promoting drug used to treat narcolepsy, is increasingly
being used as a cognitive enhancer. Although initially launched as distinct from stimu-
lants that increase extracellular dopamine by targeting dopamine transporters, recent
preclinical studies suggest otherwise.
Objective To measure the acute effects of modafinil at doses used therapeutically
(200 mg and 400 mg given orally) on extracellular dopamine and on dopamine trans-
porters in the male human brain.
Design, Setting, and Participants Positron emission tomography with [11C]ra-
clopride (D2/D3 radioligand sensitive to changes in endogenous dopamine) and [11C]co-
caine (dopamine transporter radioligand) was used to measure the effects of modafi-
nil on extracellular dopamine and on dopamine transporters in 10 healthy male
participants. The study took place over an 8-month period (2007-2008) at Brookhaven
National Laboratory.
Main Outcome Measures Primary outcomes were changes in dopamine D2/D3
receptor and dopamine transporter availability (measured by changes in binding po-
tential) after modafinil when compared with after placebo.
Results Modafinil decreased mean (SD) [11C]raclopride binding potential in caudate
(6.1% [6.5%]; 95% confidence interval [CI], 1.5% to 10.8%; P=.02), putamen (6.7%
[4.9%]; 95% CI, 3.2% to 10.3%; P=.002), and nucleus accumbens (19.4% [20%];
95% CI, 5% to 35%; P=.02), reflecting increases in extracellular dopamine. Modafi-
nil also decreased [11C]cocaine binding potential in caudate (53.8% [13.8%]; 95%
CI, 43.9% to 63.6%; P .001), putamen (47.2% [11.4%]; 95% CI, 39.1% to 55.4%;
P .001), and nucleus accumbens (39.3% [10%]; 95% CI, 30% to 49%; P=.001),
reflecting occupancy of dopamine transporters.
Conclusions In thispilot study,modafinil blockeddopamine transporters and increased
dopamine in the human brain (including the nucleus accumbens). Because drugs that in-
crease dopamine in the nucleus accumbens have the potential for abuse, and considering
the increasing use of modafinil, these results highlight the need for heightened awareness
for potential abuse of and dependence on modafinil in vulnerable populations.
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medications (methylphenidate and am-
phetamine), which increase dopamine in
brain by targeting the dopamine trans-
porters.6 It is theorized that modafinil’s
effects in the brain involve hypocretin,
histamine, epinephrine, -aminobu-
tyric acid, and glutamate.7,8 However,
there is mounting preclinical evidence
that dopamine is involved. For ex-
ample, mice lacking dopamine trans-
porters do not respond to the wake-
promoting effects of modafinil,9 and this
is also true for mice lacking D1 and D2
receptors.10 Microdialysis studies have
also reported that modafinil increases ex-
tracellular dopamine.9,11-13 In addition, a
recent imaging study in anesthetized
monkeys documented significant occu-
pancy of dopamine transporters by in-
travenously administered modafinil.14
This latter study also reported signifi-
cant occupancy of norepinephrine trans-
porters by modafinil, which in conjunc-
tion with a recent functional magnetic
resonance imaging study showing that
modafinil decreased activity in the lo-
cus coeruleus,15 highlights a role for nor-
epinephrine in modafinil’s effects.
Thegrowinguseofmodafinil inclini-
cal medicine and as a cognitive enhanc-
ingagentandtheuncertaintiessurround-
ing themechanismsunderlying itsphar-
macological effectshighlight theneed to
better understand its mechanisms of ac-
tion. Of particular relevance is the need
toresolvethequestionofwhethermodafi-
nil at the doses used therapeutically in-
creases dopamine in the human brain.
This is relevant because drugs that in-
crease dopamine in brain, particularly
those that increase dopamine in the
nucleus accumbens, a brain region criti-
cal for the rewarding effects of drugs of
abuse, have the potential for being di-
verted, and repeated use by individuals
who are vulnerable can result in addic-
tion.16 We tested the hypothesis that
modafinil, at therapeutically relevant
doses,wouldelevate extracellulardopa-
mine in thehumanbrainbyblocking the
dopaminetransporter.Wetested2doses
of modafinil: 200 mg, the dose recom-
mended for narcolepsy, and 400 mg, a
dose showntobebeneficial for the treat-
ment of ADHD.17
METHODS
Participants
This study was carried out at Brookhaven
National Laboratory from 2007 to 2008
and approved by the local institutional
review board (Committee on Research
Involving Human Subjects, State Uni-
versity of New York at Stony Brook).
Written informed consent was ob-
tained fromallparticipants after the study
had been fully explained to them. Par-
ticipants were paid for their participa-
tion and received information on poten-
tial adverse effects of modafinil during
the consenting process. Participants were
initially screened by phone and if appro-
priate were referred for evaluation by a
neurologist (F.T.) who ensured that they
met study criteria.
Ten healthy men with a mean (SD) age
of 34 (7.1) years (range, 23-46 years)
who responded to a local newspaper ad-
vertisement were selected for the study
out of 50 screened participants. Inclu-
sion criteria were male sex, nonsmok-
ing, ability to understand and give in-
formed consent, and age of 18 to 50
years. Excluded were those partici-
pants who were urine positive for psy-
choactive drugs (including phencycli-
dine, cocaine, amphetamine, opiates,
barbiturates, benzodiazepines, and tet-
rahydrocannabinol); those with clini-
cally significant abnormal laboratory val-
ues; those with history of or current
medical illness or neurological or psy-
chiatric disease (including mood fluc-
tuations); those who had used psycho-
tropic medications in the past month;
those who had experienced head trauma
with loss of consciousness longer than
30 minutes; and those with a history of
or current substance abuse (including
nicotine).
Study Design
[11C]Raclopride (dopamine D2/D3 ra-
diotracer labeled with carbon 11 that
competes for binding with endoge-
nous dopamine18) was used to serve as
an indicator of changes in extracellular
dopamine and [11C]cocaine to mea-
sure dopamine transporter availabil-
ity.18,19 Measures were obtained after
a placebo and after an oral dose of
modafinil (200 mg or 400 mg) in 10
healthy men. Using [11C]cocaine as a ra-
diotracer for the dopamine transport-
ers also afforded the opportunity to as-
sess whether modafinil binds to the same
or a closely associated site as cocaine on
dopamine transporter molecules.
Participants were scanned 4 different
times over a 2-day period (at least 1 week
apart from each other); on one day they
underwent 2 scans with [11C]cocaine,
and on another day they underwent 2
scans with [11C]raclopride. The order of
radiotracers was varied to control for po-
tential ordering effects as follows: for the
200-mg group, 3 participants received
the [11C]raclopride first and for the
400-mg group, 2 participants received
the [11C]raclopride first, whereas the rest
of the participants received the [11C]co-
caine first. We completed giving the
doses and performing the scans with the
200-mg group before the 400-mg group.
On each day, the first scan was done 2
hours after administration of placebo and
the second scan was done 2 hours after
administration of modafinil, which was
given immediately on completion of the
first scan.
Participants were blinded to whether
they would receive placebo or modafi-
nil or the dose received. Measures of
modafinil concentration in plasma
were obtained at 2 hours after modafi-
nil (corresponding to the time of scan
initiation) and analyzed using high-
performance liquid chromatography
with spectrophotometric detection
(Analytical Psychopharmacology Labo-
ratories, Nathan Kline Institute, Or-
angeburg, New York). The placebo
plasma sample served as a blank for the
measurements.
Radiotracer Synthesis
and PET Studies
[11C]Cocainewassynthesized fromnor-
cocaine(NationalInstituteonDrugAbuse
ResearchTechnologyBranch,Rockville,
Maryland) according to the literature
method.19 Radiochemical purity was
greater than98%,mean(SD)specific ac-
tivity was 61.8 (34.3) MBq/nmol at end
of synthesis, and themean(SD) injected
dosewas258(21.1)MBq.Dynamicposi-
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tron emission tomographic (PET)
imaging was carried out on a Siemens
HRhigh-resolution, whole-body PET
scanner (4.54.54.8 mm full width
athalfmaximumatcenteroffieldofview)
in three-dimension acquisition mode in
63planes(SiemensMedicalSolutionsInc,
Knoxville, Tennessee). For all scans, a
transmission scan was obtained with a
germanium 68 rotating rod source prior
totheemissionscantocorrect forattenu-
ation. Scanning was carried out for 54
minutes with the following time frames:
110 seconds, 125 seconds, 120
seconds,130seconds,460seconds,
4120 seconds, and 8300 seconds.
[11C]Raclopride was synthesized by
the literature method.20 Radiochemi-
cal purity was greater than 98%, mean
(SD) specific activity was 67.7 (42.9)
MBq/nmol at time of injection, and the
mean (SD) injected dose was 235 (29.6)
MBq. Scanning was carried out for 60
minutes with the following time frames:
110 seconds, 125 seconds, 120
seconds, 130 seconds, 860 sec-
onds, and 10300 seconds. Arterial
blood was collected over the course of
the study, and plasma was obtained and
analyzed for the fraction of carbon 11
present as the parent radiotracer.21
Drug Effect Ratings
Recordings for heart rate and blood pres-
sure were obtained continuously
throughout the study. Behavioral ef-
fects were evaluated with 2 types of
scales. Analog scales assessed self-
reports for the descriptors alert, anx-
ious, high, mood, restless, and tired, on
a scale of 1 (felt nothing) to 10 (felt
intensely).22 The Profile of Mood Scales23
is a scale widely used to assess the ef-
fects ofdrugs on mood states, which were
rated on a 10-point scale ranging from
1 (not at all) to 10 (extremely). These
measures were obtained prior to and at
2 hours and 3 hours after administra-
tion of placebo or of modafinil.
Image Processing
and Parameter Estimation
To obtain as high a signal as possible
for anatomical region identification, the
time frames were summed over the en-
tire scanning period. The summed im-
ages were resliced along the anterior
commissure–posterior commissure line
and planes were summed in groups of
2 for the purpose of placing the re-
gions of interest. For both [11C]co-
caine and [11C]raclopride, regions of
interest were placed on the caudate,
putamen, and cerebellum and then pro-
jected onto the dynamic images. For the
nucleus accumbens, since it could not
be identified clearly on the individual
images, the average image with its in-
creased signal-to-noise ratio was used
to identify the region and then pro-
jected onto the individual (coregis-
tered) images. To minimize misregis-
tration errors, the top 50 pixels from
each study were used for quantifica-
tion. The right and left sides were quan-
tified separately and then averaged after
ensuring that there were no signifi-
cant laterality effects.
Dopamine receptors and dopamine
transporters are highly concentrated in
caudate, putamen, and nucleus accum-
bens whereas their concentration in cer-
ebellum is negligible. Thus, the cerebel-
lum serves as a reference region to
control for nonspecific binding. Time-
activity curves along with the time course
of the arterial concentration of the ra-
diotracer were used to calculate K1, the
transfer constant from plasma to brain,
and the distribution volumes (VT), which
correspond to the equilibrium measure-
ment of the ratio of tissue to plasma con-
centration in the caudate, putamen,
nucleus accumbens, and cerebellum
Table. Model Terms, K1, and Binding Potential for [11C]Raclopride and [11C]Cocaine for the Placebo and Modafinil Conditions
Model Term
Mean (SD)
P Valuea
Mean Difference
Between Placebo
and Modafinil (95% CI)bPlacebo Modafinil
[11C]Raclopride
K1, mL/cc/min
Cerebellum 0.112 (0.033) 0.103 (0.015) .30 0.009 (−0.01 to 0.03)
Caudate 0.101 (0.015) 0.096 (0.013) .36 0.005 (−0.01 to 0.02)
Putamen 0.121 (0.018) 0.116 (0.013) .38 0.005 (−0.01 to 0.02)
BPND
Caudate 2.68 (0.49) 2.53 (0.56) .01 0.15 (0.04 to 0.26)
Putamen 3.44 (0.49) 3.22 (0.55) .001 0.22 (0.11 to 0.33)
Nucleus accumbens 2.89 (0.46) 2.31 (0.66) .02 0.58 (0.16 to 1.04)
[11C]Cocaine
K1, mL/cc/min
Cerebellum 0.40 (0.07) 0.44 (0.07) .01 −0.04 (−0.07 to −0.01)
Caudate 0.43 (0.08) 0.46 (0.08) .01 −0.03 (−0.06 to −0.01)
Putamen 0.49 (0.10) 0.54 (0.11) .02 −0.05 (−0.08 to −0.01)
BPND
Caudate 0.74 (0.11) 0.34 (0.19) .001 0.40 (0.31 to 0.49)
Putamen 0.95 (0.06) 0.50 (0.09) .001 0.45 (0.36 to 0.54)
Nucleus accumbens 0.86 (0.16) 0.52 (0.11) .001 0.34 (0.26 to 0.43)
Abbreviations: BPND, binding potential; CI, confidence interval; K1, transfer constant from plasma to brain.
aPaired samples t tests are shown with the corresponding 2-sided P values. Independent samples t tests show that there is no significant difference between the 200-mg and
400-mg doses for any of these variables.
bMean differences (placebo − modafinil) and 95% confidence intervals for the combined 200-mg and 400-mg dose groups.
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using graphical analysis methods for re-
versible systems.24 The ratio of the VT in
the caudate, putamen, and nucleus ac-
cumbens to that in the cerebellum is re-
ferred to as the distribution volume ra-
tio. The distribution volume ratio minus
1 corresponds to the binding potential
(BPND) and is insensitive to changes in
blood flow.25 The BPND for the caudate,
putamen, and nucleus accumbens was
used as an estimate of dopamine trans-
porter availability and D2/D3 receptor
availability after placebo and after
modafinil. Data are expressed as means
and standard deviations. There were no
missing data points.
Formation of Averaged Images
Averaging data across participants re-
duces random noise, which tends to
cancel while enhancing the signal,
which should be additive. To make im-
ages with an improved signal-to-noise
ratio, the individual time frame im-
ages for all participants in a group were
averaged. To average brains of differ-
ent shapes and sizes, we first normal-
ized them to the SPM template26 so that
all brains had corresponding struc-
tures in the same space. The blood data
from each participant were also aver-
aged for each time frame. Using the
mean dynamic image (averaged over all
participants in the group) and the av-
erage input (blood radioactivity) func-
tion, an average distribution volume im-
age was created. The BPND image was
created by dividing each voxel in the
image by the cerebellum distribution
volume and subtracting 1.
Statistics
The sample size was determined based
on results from studies that measured
dopamine transporter occupancy and
dopamine changes with 20-mg oral
methylphenidate.27,28 Primary out-
comes were changes in dopamine D2/D3
receptor and dopamine transporter
availability as measured by changes in
BPND after placebo and after modafi-
nil. Significant effects were consid-
ered for P .05 (2-tail). For dopa-
mine transporter occupancy, we
predicted a mean (SD) occupancy of
50% (5%); thus, the estimated power
of the paired t test at the significance
level of .05 (2-sided) with n=10 was
99%. For dopamine changes, we pre-
dicted a 6% (6%) change; thus, the sta-
tistical power to detect significance at
=.05 (2-sided) with n=10 was 80%.
Repeated-measures analysis of vari-
ance (ANOVA) was used to examine
the modafinil effect (placebo vs modafi-
nil), the dose effect (200 mg vs 400 mg),
and the modafinil and dose interac-
tion for K1 and BPND for both [11C]co-
caine and [11C]raclopride.
Plasmamodafinillevelswerecompared
for the 200-mg and 400-mg dose groups
andfor thesameparticipantonday1and
day 2 using repeated-measures ANOVA
(fixedeffect:dosegroups,200mgvs400
mg; repeated measures, day 1 vs day 2).
Pearson product moment correlations
were used to assess the association
between individual plasma modafinil
levels and percentage change in BPND
for [11C]cocaine and [11C]raclopride.
Repeated-measuresANOVAwasalsoused
to compare the differences between pla-
cebo and modafinil and between the 2
modafinildosesinthecardiovascularand
behavioral measures. Statistical analysis
wasperformedwithSASversion9.2(SAS
Institute Inc, Cary, North Carolina).29
RESULTS
Modafinil significantly increased heart
rate and systolic blood pressure and
these effects were significant for both
Figure 1. Averaged Positron Emission Tomography Images for After Placebo and After
Modafinil
[11C]Raclopride [11C]Cocaine
Placebo PlaceboModafinil Modafinil
Placebo PlaceboModafinil Modafinil
Striatum
Cerebellum
Averaged [11C]raclopride and [11C]cocaine binding potential (BPND) images at the level of the striatum (top row) and
cerebellum (bottom row) after placebo and after modafinil. The color scale is a rainbow scale with red representing
the highest value, which corresponds to a BPND of 4.4 in the [11C]raclopride images and a BPND of 1.1 in the [11C]co-
caine images.
Figure 2. Plasma Modafinil Concentrations
in Study Participants Who Received Either
200 mg or 400 mg of Modafinil
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Plasma modafinil concentrations were measured 2
hours after either 200 mg or 400 mg of modafinil was
administered orally on day 1 and day 2. Lines con-
nect the repeated measures for each participant, and
horizontal bars indicate the mean modafinil concen-
tration of the samples for each set.
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doses. Repeated-measures ANOVA re-
vealed a dose effect that showed higher
increases in heart rate for 400-mg than
for 200-mg modafinil (P .05). None
of the effects of modafinil on the be-
havioral measures were significant.
Repeated-measures ANOVA showed
nosignificantdoseeffect (200mgvs400
mg) nor significant dose and drug (pla-
cebo vs modafinil) interaction effect for
all BPND and K1 measures. Therefore in
thesubsequentanalysis, the200-mgand
400-mg dose groups were combined.
Modafinil produced significant reduc-
tions in BPND for [11C]raclopride and for
[11C]cocaine (TABLE), and this can be
seen in BPND images after placebo and
after modafinil for [11C]raclopride and
[11C]cocaine (FIGURE1). Modafinil de-
creasedmean(SD)[11C]racloprideBPND
in caudate (6.1% [6.5%]; 95% CI, 1.5%
to 10.8%; P=.02), putamen (6.7%
[4.9%];95%CI,3.2%to10.3%;P=.002),
and nucleus accumbens (19.4% [20%];
95% CI, 5% to 35%; P=.02), reflecting
increases in dopamine. It also decreased
[11C]cocaine BPND in caudate (53.8%
[13.8%]; 95% CI, 43.9% to 63.6%;
P.001),putamen(47.2%[11.4%];95%
CI, 39.1% to 55.4%; P .001), and
nucleusaccumbens (39.3%[10%];95%
CI, 30% to 49%;P=.001), reflecting oc-
cupancy of the dopamine transporters.
For the combined group, K1 for
[11C]cocaine (but not for [11C]raclo-
pride) was significantly elevated in cer-
ebellum, caudate, and putamen after
modafinil, indicating that the transfer
of [11C]cocaine from blood to brain was
elevated by modafinil (Table). We note
K1 is related to blood flow (F) and per-
meability surface area product (PS) by
the equation K1=F(1−e−(PS/F)).30 De-
pending on the ratio PS/F, K1 can have
values close to F (when PS is much
greater than F) or close to PS (when F
is much greater than PS). For [11C]ra-
clopride, the latter condition holds be-
cause K1 is much less than blood flow
(which is ~0.5 mL/min/cc). For [11C]co-
caine, the former condition holds be-
cause K1 is larger and closer to typical
blood flow values. Increases in cere-
bral blood flow from modafinil, which
have been documented previously,31
would therefore be more likely to be
seen as increases in K1 for [11C]co-
caine but not for [11C]raclopride.
Plasma modafinil concentrations
were compared for the 200-mg and
400-mg groups. Although the mean
(SD) 400-mg group values tended to be
higher (6.2 [2.6] µg/mL vs 4.3 [1.6] µg/
mL), repeated-measures ANOVA (fixed
effect: dose groups, 200 mg vs 400 mg;
repeated measures, day 1 vs day 2) re-
vealed that plasma modafinil concen-
trations did not differ significantly be-
tween doses (F1,8=4.36, P=.07). For the
same participant, they also did not dif-
fer between day 1 and day 2 (F1,8=2.85,
P=.13) (FIGURE 2).
There was a significant correlation
between the percentage decrease in
[11C]cocaine BPND and plasma modafi-
nil concentration, which corresponded
in caudate to R=0.87 (P .001) and
in putamen to R = 0.76 (P = .01)
(FIGURE 3). There were no significant
correlations between the percentage de-
crease in [11C]raclopride BPND and the
concentration of modafinil in plasma
(R=−0.38, P=.28, 2-sided). The corre-
lation between modafinil-induced
changes in [11C]cocaine BPND and
changes in [11C]raclopride BPND was not
significant for either the caudate
(R = 0.37, P = .30) or the putamen
(R=−0.11, P=.76, 2-sided).
COMMENT
At clinically relevant doses, modafinil
significantly increases dopamine in the
human brain by blocking dopamine
transporters. Modafinil’s binding to the
dopamine transporter overlaps with the
binding site of cocaine because [11C]co-
caine binding in striatum was inhib-
ited by modafinil. Along with the
mounting evidence from the preclini-
cal literature, this finding provides
support for the role of dopamine in
modafinil’s pharmacological actions in
humans. Thus, the hypothesis of the
nondopamine mechanism of action of
modafinil needs to be reconsidered.
The mean (SD) reductions in [11C]ra-
clopride and [11C]cocaine BPND after
modafinil were similar to those re-
ported for a 20-mg oral dose of meth-
ylphenidate in normal volunteers,
which corresponded to about 5% (6%)
for raclopride28 and to about 54% (5%)
for [11C]cocaine.27 This indicates that
modafinil at therapeutic doses pro-
duces elevations in brain dopamine
through blockade of dopamine trans-
porters, which are similar to those pro-
duced by therapeutic doses of methyl-
phenidate. Even though modafinil’s
affinity for dopamine transporters is low
Figure 3. Percentage Decrease in [11C]Cocaine Binding Potential vs Plasma Modafinil
Concentration
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Points on the plot correspond to individual participants where percentage of dopamine transporter decrease
was paired with the value of the plasma modafinil concentration measured at the time of the beginning of the
positron emission tomographic scan for both the caudate (R=0.87, P .001) and the putamen (R=0.77, P=.01).
BPND indicates binding potential. Curves were fit with linear regression.
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relative to methylphenidate (6.390 µM
vs 0.025 µM14), the therapeutic doses
are much higher for modafinil (200 mg)
than for methylphenidate (20 mg).
Drug Effects
Two doses of modafinil (200 mg and
400 mg) were evaluated, but neither the
plasma modafinil concentrations nor
the dopamine transporter blockade or
dopamine changes differed between
the 2 doses, which may reflect the
relatively small sample of the study.
The lack of a dose effect is also con-
founded by the large participant vari-
ability in modafinil’s plasma concen-
trations (particularly for 1 participant
in the 400-mg dose group) (Figure 2),
which predicted the level of dopa-
mine transporter occupancy (Figure 3).
The variability in plasma modafinil
concentration is likely to reflect vari-
ability in metabolism of modafinil. Nei-
ther modafinil’s plasma concentration
nor the level of dopamine transporter
occupancy correlated with the dopa-
mine changes. We had reported a
similar finding with methylphenidate
in which a correlation was found
between plasma concentration and
dopamine transporter occupancy, but
neither plasma concentration nor dopa-
mine transporter occupancy corre-
lated with dopamine changes.32 This re-
flects that although plasma (and
presumably brain) modafinil levels pro-
portionally compete with [11C]co-
caine for binding to the dopamine trans-
porters, decreases in [11C]raclopride
binding are a function of changes in ex-
tracellular dopamine, which are deter-
mined not only by dopamine trans-
porter blockade but also by dopamine
cell firing. For the same level of dopa-
mine transporter blockade, dopamine
changes will be greater when the ac-
tivity of dopamine cells is high than
when it is low.
Stimulant medications act as wake-
promotingagentsbyincreasingdopamine
(as well as norepinephrine) in brain.6
Modafinilwasdevelopedwithanexpec-
tation that a medication could have a
nondopaminergic target for its wake-
promotingeffects.However, thecurrent
findings inhumans, alongwithpreclini-
calstudies,9,10documentingtheindispens-
able role of dopamine in the wake-
promoting effects of modafinil, support
modafinil’sdopamine-enhancingeffects
asamechanismforitstherapeuticactions.
The dopamine-enhancing effects of
modafinil in the nucleus accumbens may
help explain reports of its abuse, since
this pharmacological effect is consid-
ered crucial for drug reinforcement.33 In-
deed, modafinil was shown to be self-
administered in monkeys previously
trained to self-administer cocaine,34 and
in humans modafinil can act as a rein-
forcer under conditions of behavioral de-
mand.35 However, modafinil is much less
potent as a reinforcer than stimulant
drugs, and reports of modafinil abuse are
rare and much less frequent than those
for stimulant drugs.36 Nonetheless, con-
sidering the broadening use of modafi-
nil and the results in this study show-
ing that it increases dopamine in the
nucleus accumbens at therapeutic doses,
its potential for abuse should not be
disregarded.
In this study, modafinil’s binding to
dopamine transporters overlapped with
the binding site of cocaine. This could
account for the findings that modafi-
nil interfered with the behavioral ef-
fects of cocaine.37 Indeed pilot studies
have reported some beneficial effects of
modafinil in the treatment of cocaine
addiction.38
Study Limitations
The [11C]raclopride method does not al-
low the exclusion of the possibility that
decreases reflect down-regulation of
D2/D3 receptors and changes in affin-
ity39 rather than dopamine increases.
Since microdialysis studies9,11-13 have
shown that modafinil increases dopa-
mine in striatum (including nucleus ac-
cumbens), this suggests that the find-
ings in this study reflect dopamine
increases. The small sample size of the
study did not provide sufficient statis-
tical power to detect dose effects. Only
healthy young men were tested, which
may limit generalizability to other popu-
lations. This study did not use a com-
plete placebo design but rather used a
placebo to compare the effects of modafi-
nil on each radiotracer, which required
that the placebo be given first and the
modafinil second, so the possibility of
an order effect cannot be ruled out. The
order of modafinil doses tested was not
randomized; instead the first 5 partici-
pants were tested with 200 mg and the
subsequent 5 with 400 mg. However, it
is unlikely that this affected the results
obtained. This study did not measure a
clinical outcome, so further studies are
necessary to assess this.
CONCLUSION
In this pilot study, modafinil acutely in-
creased dopamine levels and blocked
dopamine transporters in the human
brain. Because drugs that increase dopa-
mine have the potential for abuse, and
considering the increasing use of modafi-
nil for multiple purposes, these results
suggest that risk for addiction in vul-
nerable persons merits heightened
awareness.
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